AzTrials
AzTrials

Breast Cancer FemalePRECAMANCT03144648

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

An observational study of Breast Cancer Female, run by International Agency for Research on Cancer at 13 sites in 5 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Read more about this study

Who is it for?
Ages 20 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Breast Cancer Female
What is being tested?
lifestyle
How many people
3,000 participants
Where
13 sitesin 5 countries
Study dates
12 Oct 2012to 30 Dec 2025
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Premenopausal Latin America women

Who may be able to join

  • woman between 20 and 45 years old
  • woman less than 3 years older or younger than the case
  • living in the area that the study is taking place during the past 3 years
  • woman menstruated at least once in the past 12 months
  • woman diagnosed with a primary breast cancer by histopathological examination (only for cases)

Who cannot join

  • woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers)
  • woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol)
  • woman suffering from chronic kidney failure
  • woman having a pathology that will hinder adequate communication
  • woman who is pregnant or nursing
  • woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers)
  • any other reason to exclude

Trial locations and contacts

13 sites in 5 countries. Contact the study team or a site near you to ask about taking part.

13 sites in 5 countries

Colombia7 sites, 5 recruiting
  • Facultad de Medicina, Universidad del Norte

    Barranquilla

    Completed
  • International Hospital of Colombia

    Bucaramanga, Bucaramanga

    Ana I Orduz

    Recruiting
  • Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia

    Bucaramanga

    Norma C Serrano

    Recruiting
  • SENOSAMA foundation

    Bucaramanga

    Claudia Amaya

    Recruiting
  • Instituto de Oncología HematoOncologos

    Cali

    Completed
  • Grupo Infección y Cáncer. Universidad de Antioquia

    Medellín, Antioquia, 050010

    Gloria Sanchez, MSc, PhD, +57 3014201831, gloria.sanchez@udea.edu.co

    Maria Agudelo, MD, +57 3012974825, ceci886@hotmail.com

    Recruiting
  • Public Health University of Narino

    Pasto

    Alvaro Paz

    Recruiting

Other trials in Colombia

Chile3 sites
  • INC

    Santiago, Independencia

    Active, not recruiting
  • Hso-Crsco

    Santiago, Peñalolén

    Active, not recruiting
  • FALP

    Santiago, Providencia

    Active, not recruiting

Other trials in Chile

Brazil1 site
  • Barretos Cancer Hospital

    Barretos

    Completed

Other trials in Brazil

Costa Rica1 site
  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

    San José, Provincia de San José

    Completed

Other trials in Costa Rica

Mexico1 site
  • Instituto Nacional de Salud Pública (INSP)

    Cuernavaca, Morelos, 69100

    Completed

Other trials in Mexico

About this study

Official title: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival.

To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study).

Read more

PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following:

  1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols
  2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes
  3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes.
  4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer.

The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.

Read the detailed description

Breast cancer (BC) has become a major public health problem in Latin America (LA), as it is the most common form of cancer among women. In Women are more likely to develop BC at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from BC in LA has also been increasing very rapidly, and is currently the leading cause of cancer mortality among LA women. The large number of incident BC cases among premenopausal women, which is only partly explained by the population age-structure, is therefore of major concern. Little is known on specific risk factors for premenopausal BC in general, and in LA in particular, and risk factors related to diet, obesity and low physical activity play a role on incidence and mortality. Estrogen receptor (ER) and/or Progesterone receptor (PR) expression in breast tumors may differ according to risk factors and to molecular pathological characteristics. There is a lack of specific knowledge on tumor molecular and pathological characteristics of BC in premenopausal women, particularly in lower resource countries where the hormone-dependence status is poorly documented. This has major consequences on cancer treatment and survival.

To improve our understanding of determinants of BC incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center case-control study in LA: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study).

PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following:

  1. To develop a multi-centric population-based case-control study on BC in premenopausal women in several countries in LA with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols
  2. To characterize, in these populations, the subtypes of premenopausal BC on the basis of their molecular and pathological phenotypes
  3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes.
  4. Provide advanced training, induce a structuring effect on the BC research community in LA and influence the public health agenda regarding the management of BC.

Standardized methods and questionnaires have been developed and implemented as well as standard operating procedures for laboratory activities. Incident primary invasive cases aged 20-45 years are recruited from major cancer hospitals in four large Latin American cities (Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. Controls for the study are selected from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health history, reproductive history, use of hormones, early risk factors, body silhouette at different ages, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry (body weight, standing and sitting height, waist and hip circumferences) are measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. For all cases, highly standardized immunohistochemical and molecular analyses are performed to identify BC subtypes.

The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries in epidemiological transition, and would provide important information on the role of modifiable exposures on the disease which may provide important support for breast cancer prevention.

Being tested
lifestyle

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • lifestyleOther

    Observational study

Study groups in NCT03144648
Study groupRoleWhat they receive
CasesIncident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in five Latin American cities (Barretos, Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
Receives: Other: lifestyle
ControlsWomen with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
Receives: Other: lifestyle

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. breast cancer

    breast cancer

    Measured: at recruitment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 May 2017
  2. Study start12 Oct 2012
  3. Primary completion30 Dec 2025 (estimated)
  4. Study completion30 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
3,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03144648
Sponsor's protocol ID
PRECAMA
Acronym
PRECAMA
Status last verified
May 2025
First submitted
5 May 2017
Last updated
6 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in